Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
Metrics to compare | ALZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALZPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.8x | −2.0x | −0.7x | |
PEG Ratio | −0.26 | −0.04 | 0.00 | |
Price/Book | 1.6x | 3.4x | 2.6x | |
Price / LTM Sales | 8.2x | 10.2x | 3.4x | |
Upside (Analyst Target) | 139.0% | 92.9% | 36.2% | |
Fair Value Upside | Unlock | −5.7% | 4.1% | Unlock |